New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …

WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.

Read More

America Doesn’t Have A ‘Marijuana Problem,’ As NYT Claimsโ€”It Has a Cannabis Education …

WHY IT MATTERS: When media and policymakers frame cannabis use as a “problem” rather than an education gap, it slows the development of clinical programs, physician training, and insurance coverage that patients need to access safe, guided care. CLINICAL OVERVIEW: The framing of cannabis as a “marijuana problem” in mainstream media reflects a deeper failure in clinical education, research access, and regulatory coherence rather than an inherent danger of the plant itself. Physicians are not trained in endocannabinoid medicine during medical school, research remains federally restricted, and patients are left navigating a fragmented system without proper clinical guidance.

Read More